Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B

Area of Science:

• Hepatology
• Virology
• Clinical Medicine

Background:

• Hepatitis B e antigen (HBeAg) seroconversion can lead to inactive or HBeAg-negative chronic hepatitis B (CHB) with fluctuating alanine aminotransferase (ALT) levels.
• Predicting the clinical course in HBeAg-negative CHB is crucial for appropriate patient management.

Purpose of the Study:

• To prospectively identify factors that predict the clinical course, specifically ALT elevation, in HBeAg-negative CHB patients.
• To establish guidelines for monitoring HBeAg-negative CHB based on hepatitis B virus (HBV) DNA levels.

Main Methods:

• Prospective evaluation of 74 HBeAg-negative and 32 HBeAg-positive CHB patients over 5 years.
• Stratification by ALT and HBeAg status, with follow-up every 3 months.
• Kaplan-Meier and Cox regression analysis to identify predictors of ALT elevation/normalization.

Main Results:

• In HBeAg-negative CHB, HBV DNA levels predicted future ALT elevation.
• HBV DNA <10,000 copies/mL predicted persistently normal ALT for at least 1 year.
• HBV DNA >100,000 copies/mL was associated with a 67% risk of ALT elevation within 1 year.

Conclusions:

• HBeAg-negative CHB exhibits a fluctuating clinical course.
• HBV DNA <10,000 copies/mL predicts stable normal ALT.
• Patients with HBV DNA 10,000-100,000 copies/mL can be monitored semi-annually; those with >100,000 copies/mL require closer follow-up due to high risk of ALT elevation.